Komipharm International Co., Ltd. (KOSDAQ:041960)
South Korea · Delayed Price · Currency is KRW 8,410.00
-60.00 (-0.71%)
Apr 10, 2026, 3:30 PM KST
Komipharm International Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 52,465 | 58,779 | 42,647 | 39,801 | 35,847 |
Other Revenue | - | - | - | - | -0 |
| 52,465 | 58,779 | 42,647 | 39,801 | 35,847 | |
Revenue Growth (YoY) | -10.74% | 37.83% | 7.15% | 11.03% | -3.53% |
Cost of Revenue | 35,555 | 37,146 | 30,120 | 28,485 | 24,741 |
Gross Profit | 16,911 | 21,633 | 12,527 | 11,316 | 11,107 |
Selling, General & Admin | 11,549 | 11,741 | 10,459 | 10,004 | 9,127 |
Research & Development | 1,630 | 2,466 | 5,945 | 2,536 | 5,117 |
Amortization of Goodwill & Intangibles | 238.31 | 253.81 | 86.22 | 132.42 | 146.36 |
Other Operating Expenses | 97.43 | 236.76 | 243.5 | 251.86 | 220.89 |
Operating Expenses | 14,950 | 15,440 | 18,800 | 15,119 | 16,397 |
Operating Income | 1,960 | 6,193 | -6,273 | -3,804 | -5,291 |
Interest Expense | -2,599 | -3,206 | -2,552 | -2,216 | -1,657 |
Interest & Investment Income | 836.1 | 707.18 | 678.36 | 227.68 | 140.21 |
Currency Exchange Gain (Loss) | 47.93 | 1,109 | 235.11 | 474.93 | 1,129 |
Other Non Operating Income (Expenses) | -6,473 | 2,621 | 2,106 | 940.07 | 51.94 |
EBT Excluding Unusual Items | -6,227 | 7,425 | -5,805 | -4,377 | -5,626 |
Gain (Loss) on Sale of Investments | -383.2 | -572.32 | 248.7 | - | 13.59 |
Gain (Loss) on Sale of Assets | 1.2 | 9,073 | 64.42 | -2.43 | 0.81 |
Asset Writedown | -1,326 | -1,395 | -247.4 | -3,100 | -323 |
Other Unusual Items | - | 159.92 | - | - | - |
Pretax Income | -7,935 | 14,690 | -5,739 | -7,480 | -5,934 |
Income Tax Expense | 92.68 | - | 171.15 | - | - |
Earnings From Continuing Operations | -8,028 | 14,690 | -5,911 | -7,480 | -5,934 |
Minority Interest in Earnings | 819.07 | -1,577 | 1,932 | 965.91 | 1,475 |
Net Income | -7,209 | 13,113 | -3,979 | -6,514 | -4,459 |
Net Income to Common | -7,209 | 13,113 | -3,979 | -6,514 | -4,459 |
Shares Outstanding (Basic) | 71 | 70 | 70 | 70 | 70 |
Shares Outstanding (Diluted) | 71 | 70 | 70 | 70 | 70 |
Shares Change (YoY) | 1.32% | -0.57% | -0.18% | 0.01% | 0.09% |
EPS (Basic) | -102.00 | 188.00 | -56.72 | -92.68 | -63.45 |
EPS (Diluted) | -102.00 | 188.00 | -57.00 | -93.00 | -63.64 |
Free Cash Flow | -3,709 | 7,802 | -3,437 | -2,656 | -2,069 |
Free Cash Flow Per Share | -52.47 | 111.85 | -48.99 | -37.78 | -29.45 |
Gross Margin | 32.23% | 36.80% | 29.37% | 28.43% | 30.98% |
Operating Margin | 3.74% | 10.54% | -14.71% | -9.56% | -14.76% |
Profit Margin | -13.74% | 22.31% | -9.33% | -16.37% | -12.44% |
Free Cash Flow Margin | -7.07% | 13.27% | -8.06% | -6.67% | -5.77% |
EBITDA | 4,799 | 9,293 | -2,744 | 22.34 | -1,708 |
EBITDA Margin | 9.15% | 15.81% | -6.43% | 0.06% | -4.76% |
D&A For EBITDA | 2,838 | 3,100 | 3,529 | 3,826 | 3,582 |
EBIT | 1,960 | 6,193 | -6,273 | -3,804 | -5,291 |
EBIT Margin | 3.74% | 10.54% | -14.71% | -9.56% | -14.76% |
Advertising Expenses | 358.09 | 408.7 | 256.75 | 227.89 | 206.18 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.